[go: up one dir, main page]

MX2007005065A - Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio. - Google Patents

Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.

Info

Publication number
MX2007005065A
MX2007005065A MX2007005065A MX2007005065A MX2007005065A MX 2007005065 A MX2007005065 A MX 2007005065A MX 2007005065 A MX2007005065 A MX 2007005065A MX 2007005065 A MX2007005065 A MX 2007005065A MX 2007005065 A MX2007005065 A MX 2007005065A
Authority
MX
Mexico
Prior art keywords
dosage form
insomnia
lagged
drugs
therapy
Prior art date
Application number
MX2007005065A
Other languages
English (en)
Inventor
Guy Vergnault
Pascal Grenier
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of MX2007005065A publication Critical patent/MX2007005065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se relaciona a metodos y composiciones para tratar el insomnio, y proporciona una forma de dosis la cual contiene una sustancia de farmaco en el tratamiento del insomnio, la forma de dosis se adapta para liberar la sustancia de farmaco despues de un tiempo de retraso durante el cual substancialmente ninguna sustancia de farmaco se libera, el tiempo de retraso que es aproximadamente por lo menos una hora despues de la administracion de la forma de dosis.
MX2007005065A 2004-10-28 2005-10-28 Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio. MX2007005065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0423964.6A GB0423964D0 (en) 2004-10-28 2004-10-28 Dosage form
PCT/EP2005/011568 WO2006045618A1 (en) 2004-10-28 2005-10-28 Dosage form time-lagged of drugs for the therapy of insomnia

Publications (1)

Publication Number Publication Date
MX2007005065A true MX2007005065A (es) 2007-06-25

Family

ID=33515716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005065A MX2007005065A (es) 2004-10-28 2005-10-28 Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.

Country Status (14)

Country Link
US (1) US20090297601A1 (es)
EP (2) EP1814529B1 (es)
JP (3) JP2008517970A (es)
KR (2) KR20070090895A (es)
CN (2) CN101076321A (es)
AU (1) AU2005298854B2 (es)
BR (1) BRPI0517391A (es)
CA (1) CA2585910C (es)
GB (1) GB0423964D0 (es)
IL (1) IL182849A0 (es)
MX (1) MX2007005065A (es)
RU (1) RU2458685C2 (es)
WO (1) WO2006045618A1 (es)
ZA (1) ZA200703810B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107878A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Solid dosage forms of hypnotic agent
EP2375903A4 (en) * 2008-12-15 2012-09-19 Somnus Therapeutics Inc METHOD FOR TREATING SILENTNESS
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
CN102824327A (zh) * 2011-06-14 2012-12-19 天津药物研究院 含有阿戈美拉汀的肠溶片的药用组合物
CN102949376A (zh) * 2011-08-25 2013-03-06 天津药物研究院 一种含阿戈美拉汀的肠溶胶囊的药用组合物
CN102824331A (zh) * 2012-09-28 2012-12-19 河南中帅医药科技发展有限公司 扎来普隆双释放胶囊及其制备方法
HUE036989T2 (hu) * 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
EP3632416A1 (en) * 2014-02-06 2020-04-08 Lan Bo Chen Composition and method for aiding sleep
MX386901B (es) * 2014-04-25 2025-03-19 Chugai Pharmaceutical Co Ltd Formulacion que contiene una gran cantidad de compuesto tetraciclico.
CN104306349B (zh) * 2014-09-11 2017-08-25 常州欧法玛制药技术有限公司 一种含褪黑素的渗透泵控释片及其配制方法
CN104434848A (zh) * 2014-11-27 2015-03-25 河南中帅医药科技股份有限公司 一种择时释放的口服固体制剂及其制备方法
CN105640905B (zh) * 2014-12-02 2018-06-22 上海美迪西生物医药股份有限公司 氟硝西泮舌下片制剂及其制备方法
RU2694837C2 (ru) * 2017-07-06 2019-07-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтическая композиция пролонгированного действия на основе 5-этокси-2-[2-(морфолино)-этилтио] бензимидазола дигидрохлорида и/или основания (Афобазола)
CN113274364B (zh) * 2021-07-22 2021-12-07 海南慧谷药业有限公司 雷美替胺缓释制剂及其制备方法
CN113274365B (zh) * 2021-07-22 2021-10-22 广东科泰鼎润药业科技有限公司 雷美替胺速释缓释双释放制剂及其制备方法
CN120154581A (zh) * 2021-08-18 2025-06-17 越洋医药开发(广州)有限公司 允许睡眠调节类药物分段释放的片剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
JPS63215620A (ja) * 1987-03-03 1988-09-08 Nippon Soda Co Ltd 徐放性製剤
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
ATE133331T1 (de) * 1991-11-13 1996-02-15 Glaxo Canada Vorrichtung zur kontrollierten wirkstoffreigabe
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
JP2003507413A (ja) * 1999-08-26 2003-02-25 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 徐放性鎮静催眠組成物およびそれに関連する方法
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
EP1368000A4 (en) * 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
CN100408029C (zh) * 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
BRPI0407074A (pt) * 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
AP3803A (en) * 2012-02-08 2016-08-31 Univ Johannesburg Witwatersrand Pharmaceutical dosage form

Also Published As

Publication number Publication date
EP1814529A1 (en) 2007-08-08
KR20070090895A (ko) 2007-09-06
GB0423964D0 (en) 2004-12-01
RU2458685C2 (ru) 2012-08-20
CN103394087A (zh) 2013-11-20
US20090297601A1 (en) 2009-12-03
EP2298289A1 (en) 2011-03-23
RU2007118585A (ru) 2008-12-10
JP2013177420A (ja) 2013-09-09
AU2005298854B2 (en) 2012-10-04
AU2005298854A1 (en) 2006-05-04
CA2585910A1 (en) 2006-05-04
JP6233985B2 (ja) 2017-11-22
JP2008517970A (ja) 2008-05-29
CN101076321A (zh) 2007-11-21
BRPI0517391A (pt) 2008-10-07
CA2585910C (en) 2013-12-17
WO2006045618A1 (en) 2006-05-04
EP1814529B1 (en) 2016-07-20
JP2016183179A (ja) 2016-10-20
IL182849A0 (en) 2007-08-19
ZA200703810B (en) 2008-06-25
KR20130089288A (ko) 2013-08-09

Similar Documents

Publication Publication Date Title
MX2007005065A (es) Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
AR050418A1 (es) Dosificacion fija de anticuerpos her
WO2005107726A3 (en) Method for the treatment of back pain
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
MY199903A (en) Combination therapy with controlled-release cnp agonists
TW200738228A (en) Neramexane modified release matrix tablet
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
ATE394097T1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
NZ598370A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
GB2446341A (en) Method and system for transdermal drug delivery
WO2007144081A3 (de) Raucherentwöhnungs-kombinationswafer
UA81689C2 (ru) Способ предоперационного лечения послеоперационной боли бупренорфином
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
WO2007093519A3 (en) Ibandronate regimen for treating metastatic bone pain
WO2007135123A3 (en) Mirtazapine for the treatment of neuropathic pain
SA522432821B1 (ar) توليفة من ميرتازابين وتيزانيدين للاستخدام في اضطرابات الألم

Legal Events

Date Code Title Description
FG Grant or registration